These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 16926600

  • 1. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M.
    Transplantation; 2006 Aug 27; 82(4):550-7. PubMed ID: 16926600
    [Abstract] [Full Text] [Related]

  • 2. Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients.
    San Segundo D, Ruiz JC, Fernández-Fresnedo G, Izquierdo M, Gómez-Alamillo C, Cacho E, Benito MJ, Rodrigo E, Palomar R, López-Hoyos M, Arias M.
    Transplant Proc; 2006 Oct 27; 38(8):2391-3. PubMed ID: 17097943
    [Abstract] [Full Text] [Related]

  • 3. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
    San Segundo D, Fábrega E, López-Hoyos M, Pons F.
    Transplant Proc; 2007 Sep 27; 39(7):2290-2. PubMed ID: 17889166
    [Abstract] [Full Text] [Related]

  • 4. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice.
    Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, Zeng C, Zhao Y.
    Transpl Immunol; 2007 Apr 27; 17(3):153-61. PubMed ID: 17331841
    [Abstract] [Full Text] [Related]

  • 5. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 6. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP3+ regulatory T-cells in patients after kidney transplantation.
    van de Wetering J, Koumoutsakos P, Peeters A, van der Mast BJ, de Kuiper P, IJzermans JN, Weimar W, Baan CC.
    Clin Transplant; 2011 Aug 27; 25(1):40-6. PubMed ID: 20636406
    [Abstract] [Full Text] [Related]

  • 7. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs.
    Bocian K, Borysowski J, Wierzbicki P, Wyzgal J, Klosowska D, Bialoszewska A, Paczek L, Górski A, Korczak-Kowalska G.
    Nephrol Dial Transplant; 2010 Mar 27; 25(3):710-7. PubMed ID: 19903662
    [Abstract] [Full Text] [Related]

  • 8. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y, Shi Y, Huang Z, Bai Y, Niu Q, Cai B, Wang L, Feng W.
    Int Immunopharmacol; 2011 Dec 27; 11(12):2033-8. PubMed ID: 21911083
    [Abstract] [Full Text] [Related]

  • 9. Quantitative analysis of regulatory T cells in kidney graft recipients: a relationship with calcineurin inhibitor level.
    Calvo-Turrubiartes M, Romano-Moreno S, García-Hernández M, Chevaile-Ramos JA, Layseca-Espinosa E, González-Amaro R, Portales-Pérez D.
    Transpl Immunol; 2009 May 27; 21(1):43-9. PubMed ID: 19233271
    [Abstract] [Full Text] [Related]

  • 10. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.
    Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035
    [Abstract] [Full Text] [Related]

  • 11. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V, Abraham G, Fathima N, Sundaram V, Reddy YN, Mathew M, Sathiah V.
    Saudi J Kidney Dis Transpl; 2010 Jan 15; 21(1):37-42. PubMed ID: 20061690
    [Abstract] [Full Text] [Related]

  • 12. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation.
    Korczak-Kowalska G, Wierzbicki P, Bocian K, Klosowska D, Niemczyk M, Wyzgal J, Korecka A, Durlik M, Chmura A, Paczek L, Górski A.
    Transplant Proc; 2007 Nov 15; 39(9):2721-3. PubMed ID: 18021968
    [Abstract] [Full Text] [Related]

  • 13. Low circulating regulatory T-cell levels after acute rejection in liver transplantation.
    Demirkiran A, Kok A, Kwekkeboom J, Kusters JG, Metselaar HJ, Tilanus HW, van der Laan LJ.
    Liver Transpl; 2006 Feb 15; 12(2):277-84. PubMed ID: 16447185
    [Abstract] [Full Text] [Related]

  • 14. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation.
    Wang X, Wang W, Xu J, Le Q.
    Transplant Proc; 2013 Mar 15; 45(2):528-37. PubMed ID: 23267787
    [Abstract] [Full Text] [Related]

  • 15. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction.
    Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK.
    Transplant Proc; 2007 Mar 15; 39(2):518-21. PubMed ID: 17362772
    [Abstract] [Full Text] [Related]

  • 16. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.
    J Heart Lung Transplant; 2009 Jun 15; 28(6):564-71. PubMed ID: 19481016
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus did not affect CD4(+)CD25(high) forkhead box p3(+)T cells of peripheral blood in renal transplant recipients.
    Chu ZQ, Ji Q.
    Transplant Proc; 2013 Jun 15; 45(1):153-6. PubMed ID: 23375290
    [Abstract] [Full Text] [Related]

  • 18. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 Jun 15; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 20. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 27; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.